Patent US4701455A successfully refreshed from Google Patents.
US4701455A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Biopterin analogs
Assignee: SmithKline Beecham Corp
•
Filing: 1985-06-21
•
Granted: 1987-10-20
•
Expires: 2005-06-21
Abstract
Abstract This invention provides the pterin compounds of formula (I) and use in human and veterinary medicine. <IMAGE> I wherein R represents lower alkyl groups (straight or branched) of 1-8 carbons (for this formula and all other formulas herein) including all stereo isomers thereof or a pharmaceutically acceptable salt thereof.
Inventors
- 👤 Charles A. Nichol
- 👤 John F. Reinhard, Jr.
- 👤 Gary K. Smith
- 👤 Eric C. Bigham
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 08:39
CPC Classifications
C; C07; C07D; C07D475/00; C07D475/06; C07D475/08; C07D241/00; C07D241/02; C07D241/10; C07D241/14; C07D241/24; C07D241/26; C07D475/02; C07D475/04
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
24 words
A compound of formula (I) ##STR7## wherein R represents lower alkyl groups (straight or branched) of 1-8 carbons or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
24 words
A compound of formula (I) ##STR7## wherein R represents lower alkyl groups (straight or branched) of 1-8 carbons or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
5 words
A compound which is (+-)-2-amino-5,6,7,8-tetrahydro-6-methoxymethyl-4(3H)-pteridinone.
Claim 4
Dependent Claim
5 words
A compound which is (+-)-2-amino-5,6,7,8-tetrahydro-6-methoxymethyl-4(3H)-pteridinone.
Claim 5
Dependent Claim
5 words
A compound which is (+-)-2-amino-5,6,7,8-tetrahydro-6-n-butoxymethyl-4(3H)-pteridinone.
Claim 6
Dependent Claim
5 words
A compound which is (+-)-2-amino-5,6,7,8-tetrahydro-6-n-butoxymethyl-4(3H)-pteridinone.
Claim 7
Dependent Claim
52 words
A method of treating a disorder arising from deficiencies of catecholamines and/or serotinin at the pre-synaptic site of neuronal junctions in a mammal including a human consisting of administering to said mammal an effective amount of a compound of formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
11 words
A method of claim 4 wherein the disorder is Parkinson's disease.
Claim 9
Dependent Claim
21 words
A method of claim 5 wherein a compound of formula (I) is (+-)-2-amino-5,6,7,8-tetrahydro-6-methoxymethyl-4(3H)-pteridinone or a pharmaceutically acceptable salt thereof is administered.
Claim 10
Dependent Claim
21 words
A method of claim 5 wherein a compound of formula (I) is (+-)-2-amino-5,6,7,8-tetrahydro-6-n-butoxymethyl-4(3H)-pteridinone or a pharmaceutically acceptable salt thereof is administered.
Claim 11
Dependent Claim
11 words
A method of claim 4 wherein the disorder is endogenous depression.
Claim 12
Dependent Claim
21 words
A method of claim 8 wherein a compound of formula (I) is (+-)-2-amino-5,6,7,8-tetrahydro-6-methoxymethyl-4(3H)-pteridinone or a pharmaceutically acceptable salt thereof is administered.
Claim 13
Dependent Claim
21 words
A method of claim 8 wherein a compound of formula (I) is (+-)-2-amino-5,6,7,8-tetrahydro-6-n-butoxymethyl-4(3H)-pteridinone or a pharmaceutically acceptable salt thereof is administered.
Claim 14
Dependent Claim
11 words
A method of claim 4 wherein the disorder is orthostatic hypotension.
Claim 15
Dependent Claim
21 words
A method of claim 11 wherein a compound of formula (I) is (+-)-2-amino-5,6,7,8-tetrahydro-6-methoxymethyl-4(3H)-pteridinone or a pharmaceutically acceptable salt thereof is administered.
Claim 16
Dependent Claim
21 words
A method of claim 11 wherein a compound of formula (I) is (+-)-2-amino-5,6,7,8-tetrahydro-6-n-butoxymethyl-4(3H)-pteridinone or a pharmaceutically acceptable salt thereof is administered.
Claim 17
Dependent Claim
11 words
A method of claim 4 wherein the disorder is muscular dystonia.
Claim 18
Dependent Claim
21 words
A method of claim 14 wherein a compound of formula (I) is (+-)-2-amino-5,6,7,8-tetrahydro-6-methoxymethyl-4(3H)-pteridinone or a pharmaceutically acceptable salt thereof is administered.
Claim 19
Dependent Claim
21 words
A method of claim 14 wherein a compound of formula (I) is (+-)-2-amino-5,6,7,8-tetrahydro-6-n-butoxymethyl-4(3H)-pteridinone or a pharmaceutically acceptable salt thereof is administered.
Claim 20
Dependent Claim
11 words
A method of claim 4 wherein the disorder is atypical PKU.
Claim 21
Dependent Claim
10 words
A pharmaceutically acceptable salt of (+-)-2-amino-5,6,7,8-tetrahydro-6-methoxymethyl-4(3H)-pteridinone according to claim 1.
Claim 22
Dependent Claim
10 words
A pharmaceutically acceptable salt of (+-)-2-amino-5,6,7,8-tetrahydro-6-n-butoxy-methyl-4(3H)-pteridinone according to claim 1.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-10-19 | 1991-04-20 | 1991-10-20 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-10-19 | 1995-04-20 | 1995-10-20 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-10-19 | 1999-04-20 | 1999-10-20 | $7700.00 | Window Closed / Lapsed |